Mdl-1 ligand
OwnerBarbara Joyce-Shaikh, Douglas C. Wilson +7inventors
InventorsBarbara Joyce-Shaikh, Douglas C. Wilson, Daniel J. Cua, Drake M. LaFace, Marbel Beaumont, Holly Cherwinski, Mark Hsieh, Sabrina Benchaar, Joseph H. Philips
Life of this patent
Estimating the term…
Abstract
The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.
Claims19
A method of modulating an interaction between a lectin-like molecule expressed on myeloid cells, and a lectin which binds to a receptor expressed by a T cell, the method comprising:
- a) providing a compound that is capable of binding to lectin-like molecule at a binding site of the lectin;
- and
- b) presenting the compound of step (i) to lectin-like molecule and the lectin and thereby modulating the interaction between the first and second lectin.
A method of screening for a compound that modulates an interaction between a first lectin-like molecule expressed on myeloid cells, and a lectin which binds to a receptor expressed by a T cell, the method comprising:
- a) providing a compound that is capable of binding to the lectin-like molecule at a binding site of the lectin;
- and
- b) presenting the compound of step (a) to the lectin-like molecule and the second lectin and thereby modulating the interaction between the first and second lectin.
A method of depleting a population of T lymphocyte cells comprising contacting the population of T lymphocyte cells with an MDL-1 fusion protein that binds directly or indirectly to a molecule expressed on the T lymphocyte cells.
Dependencies are inferred from the claim text.